Oncology Market Leaders Maintain Their Upper Hand
Executive Summary
Drugs like Ibrance and Lynparza show that in the cancer market, it can be hard for new entrants to catch early standouts.
You may also be interested in...
GSK's Zejula Poised To Take On Lynparza In First-Line Ovarian Cancer
The Phase III PRIMA study in first-line ovarian cancer was positive for progression-free survival in patients regardless of their biomarker status, GSK reported.
Sanofi Myeloma Drug Shines But Darzalex Dominates Still
While data on Sanofi's anti-CD38 antibody isatuximab impressed at ASCO, analysts believe that the position of Johnson & Johnson's Darzalex in the multiple myeloma space is unlikely to be threatened.
Novartis' Kisqali Scores Big Win In Competitive CDK4/6 Space
Data at ASCO showed a statistically significant overall survival advantage in pre- and perimenopausal women with advanced HR+, HER2- breast cancer, a first for the CDK4/6 class.